Dr. Kim discusses why non-small cell lung cancer should be considered the paradigm for precision medicine, and how treatment of the disease has changed over the last decade.
In a recent sub-analysis, lenvatinib was shown to improve both progression-free and overall survival in older patients with radioiodine-refractory thyroid cancer.
In this video, Gareth J. Morgan, MD, discusses the new biologic advances in multiple myeloma and how they are currently being applied to clinical practice.
In this video, Dr. Edward Kim provides details on the TAPUR trial, which uses broad genomic test results to aid in precision medicine for cancer patients.
In this podcast interview, Dr. Hossein Borghaei discusses some of the latest science presented at ASCO that focuses on immunotherapy in lung cancer.
Results from a nationwide clinical trial, which were presented at the 2017 ASCO Annual Meeting, indicate that adding pembrolizumab to standard therapy before surgery offers the potential for improving outcomes in this patient population.
We spoke with Dr. Priya Kumthekar and Dr. Alexander Stegh about their nucleic acid-based therapeutic development that targets glioblastoma.
Lenalidomide plus rituximab induction therapy followed by maintenance appears to provide favorable activity and a tolerable safety profile in follicular lymphoma patients who are double-refractory or had early relapse after initial diagnosis.
Anti-CD19 CAR T-cell therapy may benefit patients with aggressive B-cell non-Hodgkin lymphoma who have relapsed or are refractory to standard therapy.
CAR T-cell therapy may have a role in combating relapsed/refractory multiple myeloma, according to new data from a phase I study presented at the 2017 ASCO Annual Meeting, held June 2–6 in Chicago.
Brentuximab vedotin, a monoclonal antibody-drug conjugate, combined with gemcitabine may be a new treatment option for children and AYAs with relapsed or refractory Hodgkin lymphoma.
A two-pronged algorithm, which includes an analysis for a gene signature and tumor mutational burden, may be a potential new tool for predicting treatment response to checkpoint inhibitors.
As healthcare providers caring for oncology patients, we are all too familiar with the physical effects of chemotherapy, including chemobrain. A University of Kansas researcher may have identified a possible therapy to prevent this side effect.
A 43-year-old woman presents with a mass in the brain. What is your diagnosis?